Clinical Trials Directory

Trials / Sponsors / Moberg Pharma AB

Moberg Pharma AB

Industry · 14 registered clinical trials.

StatusTrialPhaseStarted
Active Not RecruitingA Vehicle-controlled Study of Topical MOB015B in the Treatment of Distal Subungual Onychomycosis (DSO)
Onychomycosis
Phase 32022-05-09
CompletedA Study of the Systemic Absorption of MOB015B
Onychomycosis
Phase 12017-12-16
CompletedSkin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design
Erythema
Phase 12017-10-19
CompletedStudy to Evaluate the Sensitizing Potential of MOB015B in Healthy Subjects Using a Repeat Insult Patch Test De
Erythema
Phase 12017-10-15
CompletedA Multi-centre, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B i
Distal Subungual Onychomycosis
Phase 32016-10-01
CompletedStudy to Evaluate the Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subun
Distal Subungual Onychomycosis
Phase 32016-09-01
CompletedAn Open,Single-centre Pilot Study of Efficacy and Safety of Topical MOB015B in the Treatment of Distal Subungu
Distal Subungual Onychomycosis
Phase 22012-12-01
CompletedEfficacy and Safety of Two Treatment Regimens of Topical MOB015 in Adults With Distal Subungual Onychomycosis
Onychomycosis
Phase 22010-12-01
CompletedA Clinical Investigation on Early Visible Effects of Application of K101 During 8 Weeks on Discoloured and Def
Onychomycosis
N/A2010-09-01
CompletedK301 for the Treatment of Seborrhoeic Eczema (SE) of the Scalp
Seborrhoeic Eczema of the Scalp
Phase 32008-02-01
CompletedTwo Topical K40 Formulations in Adults With Seborrhoeic Dermatitis (SD) of the Scalp
Seborrhoeic Dermatitis of the Scalp
Phase 2 / Phase 32007-02-01
CompletedA Double-blind, Randomized, Single Centre, Vehicle-controlled Study to Evaluate the Safety and Tolerability of
Healthy
Phase 1—
CompletedAssessment of the Effects on Barrier Impairment, Clinical Features and Bacterial Colonization of Topical Formu
Atopic Dermatitis
Phase 1 / Phase 2—
CompletedEfficacy and Safety of a New Topical Formulation With Imiquimod (Limtop) Applied 1, 3 or 7 Times Weekly During
Actinic Keratosis
Phase 2—